Seres therapeutics and nestlÉ health science announce fda approval of vowsttm (fecal microbiota spores, live-brpk) for prevention of recurrence of c. difficile infection in adults following antibacterial treatment for recurrent cdi

Cambridge, mass. & hoboken, n.j.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) and nestlÉ health science today announced the u.s. food and drug administration (fda) approval of vowsttm (fecal microbiota spores, live-brpk), formerly called ser-109, an orally administered microbiota-based therapeutic to prevent recurrence of c. difficile infection (cdi) in adults following antibacterial treatment for recurrent cdi (rcdi). vowst is not indicated for the treatment of cdi. “since being f.
MCRB Ratings Summary
MCRB Quant Ranking